{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:52:53Z","timestamp":1784173973321,"version":"3.55.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) in adolescents is a more rapidly progressive disease, associated with earlier and higher rates of microvascular complications than in adults. As obesity is a significant risk factor for T2DM development and progression, the American Diabetes Association (ADA) recommends anti-obesity medications (AOMs) as adjuvant therapy for adults with both T2DM and overweight\/obesity. In adults, the addition of AOMs to a diabetes regimen can improve glycemic control, reduce weight, and decrease anti-diabetes medication use. The ADA recommends considering bariatric surgery for adolescents with T2DM who have a BMI &amp;gt;35 kg\/m<jats:sup>2<\/jats:sup>, but did not mention the use of AOMs in their 2022 updated guidelines. Currently, there are three FDA-approved AOMs available for chronic use in adolescents with obesity. Other medications are used in an \u201coff-label\u201d fashion for appetite suppression and BMI reduction. As additional AOMs are being developed and FDA-approved for the pediatric population, new treatment options with novel mechanisms of action will become available for adolescents with T2DM and obesity. In this review, we will discuss the evidence for the use of AOMs in the treatment of T2DM in adolescents, including lessons learned from the adult T2DM literature.<\/jats:p>","DOI":"10.3389\/fendo.2022.1043650","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T05:50:43Z","timestamp":1666849843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults"],"prefix":"10.3389","volume":"13","author":[{"given":"Megan O.","family":"Bensignor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Arslanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00044","article-title":"Body mass index and incident type 1 and type 2 diabetes in children and young adults: A retrospective cohort study","volume":"1","author":"Abbasi","year":"2017","journal-title":"J Endocr Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/obr.12316","article-title":"Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta-analysis","volume":"17","author":"Llewellyn","year":"2016","journal-title":"Obes Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01474.x","article-title":"A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin","volume":"22","author":"Berne","year":"2005","journal-title":"Diabetes Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. a 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90299-R","article-title":"UK Prospective diabetes study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients","volume":"39","year":"1990","journal-title":"Metabolism."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.5763","article-title":"Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents","volume":"172","author":"Inge","year":"2018","journal-title":"JAMA Pediatr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.04.003","article-title":"Threshold for improvement in insulin sensitivity with adolescent weight loss","volume":"163","author":"Abrams","year":"2013","journal-title":"J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12148","article-title":"Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience","volume":"12","author":"Marcus","year":"2017","journal-title":"Pediatr Obes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.10.1499","article-title":"Intentional weight loss and mortality among overweight individuals with diabetes","volume":"23","author":"Williamson","year":"2000","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1990.tb01375.x","article-title":"Obesity, weight loss and prognosis in type 2 diabetes","volume":"7","author":"Lean","year":"1990","journal-title":"Diabetes Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0052","article-title":"Evaluation and management of youth-onset type 2 diabetes: A position statement by the American diabetes association","volume":"41","author":"Arslanian","year":"2018","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3494","article-title":"Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents","volume":"131","author":"Copeland","year":"2013","journal-title":"Pediatrics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pedi.12719","article-title":"ISPAD clinical practice consensus guidelines 2018: Type 2 diabetes mellitus in youth","author":"Zeitler","year":"2018","journal-title":"Pediatr Diab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S014","article-title":"14:Children and adolescents: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.01.009","article-title":"Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study","volume":"89","author":"Narasimhan","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41387-018-0057-6","article-title":"Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study","volume":"8","author":"Lentferink","year":"2018","journal-title":"Nutr Diab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2019.0040","article-title":"Metformin therapy reduces obesity indices in children and adolescents: A systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Sadeghi","year":"2020","journal-title":"Child Obes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s11892-014-0568-z","article-title":"Lifestyle therapy for the treatment of youth with type 2 diabetes","volume":"15","author":"McGavock","year":"2015","journal-title":"Curr Diabetes Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0787","article-title":"Impact of insulin and metformin versus metformin alone on \u03b2-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B26","unstructured":"FDA Approves treatment for chronic weight management in pediatric patients aged 12 years and older2022"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2573","article-title":"Pediatric obesity-assessment, treatment, and prevention: An endocrine society clinical practice guideline","volume":"102","author":"Styne","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2012.08.003","article-title":"Evaluation of appetite-stimulating hormones in prepubertal children with epilepsy during topiramate treatment","volume":"47","author":"Okuyaz","year":"2012","journal-title":"Pediatr Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813909","article-title":"Teen\u2013LABS consortium. five-year outcomes of gastric bypass in adolescents as compared with adults","volume":"380","author":"Inge","year":"2019","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2021","journal-title":"Lancet."},{"key":"B31","unstructured":"Orlistat (marketed as allli and xenical) information2015"},{"key":"B32","unstructured":"FDA Approves weight management drug for patients aged 12 and older2020"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.84","article-title":"Topiramate reduces energy and fat gains in lean (Fa\/?) and obese (fa\/fa) zucker rats","volume":"8","author":"Picard","year":"2000","journal-title":"Obes Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801873","article-title":"The effects of topiramate and sex hormones on energy balance of male and female rats","volume":"26","author":"Richard","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2011.04.046","article-title":"Glutamate and GABA in lateral hypothalamic mechanisms controlling food intake","volume":"104","author":"Stanley","year":"2011","journal-title":"Physiol Behav"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0220-1","article-title":"The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension","volume":"63","author":"Tremblay","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0258","article-title":"Comprehensive review of current and upcoming anti-obesity drugs","volume":"44","author":"Son","year":"2020","journal-title":"Diabetes Metab J"},{"key":"B38","unstructured":"Highlights of prescribing information: Qsymia (phentermine and topiramate extended-release)2013"},{"key":"B39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/oby.22385","article-title":"Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity","volume":"27","author":"Srivastava","year":"2019","journal-title":"Obes (Silver Spring)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly","year":"2022","journal-title":"New Engl J Med Evidence"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B42","volume-title":"Pathogenesis of type 2 diabetes mellitus","author":"Solis-Herrera","year":"2021"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2501","article-title":"Incretins: their physiology and application in the treatment of diabetes mellitus","volume":"30","author":"Tasyurek","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(19)30236-6","article-title":"FDA Approval of GLP-1 receptor agonist (liraglutide) for use in children","volume":"3","author":"Bacha","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"B45","unstructured":"Safety and efficacy study of exenatide once weekly in adolescents with type 2 diabetes2022"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2275","article-title":"Once-weekly exenatide in youth with type 2 diabetes","volume":"45","author":"Tamborlane","year":"2022","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12778","article-title":"Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial","volume":"16","author":"Bensignor","year":"2021","journal-title":"Pediatr Obes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/pedi.12846","article-title":"Trends in prevalence of cardiovascular risk factors from 2002 to 2012 among youth early in the course of type 1 and type 2 diabetes. the SEARCH for diabetes in youth study","volume":"20","author":"Kim","year":"2019","journal-title":"Pediatr Diab"},{"key":"B51","unstructured":"Highlights of prescribing information: Wegovy (semaglutide) injection, for subcutaneous use2022"},{"key":"B52","unstructured":"A research study on how well semaglutide works in adolescents with overweight and obesity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2042018820918789","DOI":"10.1177\/2042018820918789","article-title":"Medications for the treatment of obesity in adolescents","volume":"11","author":"Woodard","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2004.17.3.307","article-title":"Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions","volume":"17","author":"McDuffie","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"key":"B57","unstructured":"Highlights of prescribing information: Contrave (naltrexone HCl and bupropion HCl) extended related tablets2014"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature05026","article-title":"Central nervous system control of food intake and body weight","volume":"443","author":"Morton","year":"2006","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.11.010","article-title":"Effects of amylin and bupropion\/naltrexone on food intake and body weight are interactive in rodent models","volume":"698","author":"Clapper","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obes (Silver Spring)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20120806-09","article-title":"The relationship between obesity and depression among adolescents","volume":"42","author":"Nemiary","year":"2012","journal-title":"Psychiatr Ann"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0431","article-title":"Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study","volume":"34","author":"Anderson","year":"2011","journal-title":"Diabetes Care"},{"key":"B63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12519-021-00485-2","article-title":"Prevalence of depression and anxiety among children with type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Akbarizadeh","year":"2022","journal-title":"World J Pediatr"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1111\/pedi.13093","article-title":"Glycemic control in youth-onset type 2 diabetes correlates with weight loss","volume":"21","author":"Chang","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1111\/pedi.12761","article-title":"Treatment adherence and BMI reduction are key predictors of HbA1c 1 year after diagnosis of childhood type 2 diabetes in the United Kingdom","volume":"19","author":"Candler","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2534","article-title":"Treatment effects on measures of body composition in the TODAY clinical trial","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"Zeitler","year":"2012","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S008","article-title":"8. obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1043650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T05:50:50Z","timestamp":1666849850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1043650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":68,"alternative-id":["10.3389\/fendo.2022.1043650"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1043650","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"article-number":"1043650"}}